GlaxoSmithKline plc (GSK): What Is The Development In Terms Of Pipeline Development & Recent Technological Advancements? 

GSK has reported a robust start to the year with notable growth in both sales and profits, driven by strong execution and successful product launches. Total sales increased by 13% to GBP 7.4 billion, with core operating profit surging by 35% to GBP 2.4 billion, and core earnings per share growing by 37% to 43.1p. These figures exclude contributions from COVID solutions, underscoring the company’s success in its core operations. GSK’s focus on innovation is evident through the significant growth across its innovative vaccines and specialty medicines, fueled by new products such as the RSV vaccine Arexvy and the Shingrix vaccine.